Synopsis
Synopsis
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3-amino-9,13b-dihydro-1h-benz(c,f)imidazo(1,5a)azepine
2. Epinastine
3. Flurinol
4. Wal 80
5. Wal 801
6. Wal 801 Cl
7. Wal 801cl
8. Wal-80 Cl
1. Epinastine Hcl
2. 108929-04-0
3. Alesion
4. Elestat
5. Wal-801cl
6. 80012-44-8
7. Wal 801 Cl
8. Epinastine Hydrochloride [jan]
9. De-114
10. Epinastine (hydrochloride)
11. Epinastinehydrochloride
12. Gfm415s5xl
13. Wal-802-cl
14. Wal801
15. Relestat
16. 3-amino-9,13b-dihydro-1h-dibenzo[c,f]imidazo[1,5-a]azepine Hydrochloride
17. 9,13b-dihydro-1h-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine Hydrochloride
18. Dsstox_cid_26502
19. Dsstox_rid_81671
20. Dsstox_gsid_46502
21. Epinastine Hydrochloride (jan)
22. Epinastine Monohydrochloride
23. Chebi:51037
24. Cas-108929-04-0
25. Ncgc00165791-02
26. Unii-gfm415s5xl
27. Flurinol
28. (13brs)-9,13b-dihydro-1h-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine Hydrochloride
29. Alesion (tn)
30. Elestat (tn)
31. Mfcd00933434
32. Epinastin Hydrochloride
33. 9,13b-dihydro-1h-dibenz[cf]imidazo[1,5-a]azepine Hydrochloride
34. Wal-801cl Hcl
35. 3-amino-9,13b-dihydro-1h-dibenz(c,f)imidazo(1,5-a)azepine Monohydrochloride
36. Schembl122749
37. Chembl1200491
38. Dtxsid1046502
39. Epinastine For System Suitability
40. Hy-b0640a
41. Hms3652n21
42. Hms3885b15
43. Bcp12119
44. Ex-a1004
45. Tox21_112263
46. Tox21_500501
47. Epinastine Hydrochloride [mi]
48. S4253
49. Akos015967222
50. Tox21_112263_1
51. Ac-1491
52. Ccg-221805
53. Ks-1159
54. Lp00501
55. Epinastine Hydrochloride [mart.]
56. Ih-dibenz(c,f)imidazo(1,5-a)azepin-3-amine, 9,13b-dihydro-, Monohydrochloride
57. Epinastine Hydrochloride [usp-rs]
58. Epinastine Hydrochloride [who-dd]
59. Ncgc00165791-04
60. Ncgc00261186-01
61. 2,4-diazatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine;hydrochloride
62. Db-040850
63. Cs-0013220
64. E0799
65. Ft-0631049
66. Ft-0700527
67. Sw220223-1
68. Epinastine Hydrochloride [orange Book]
69. D01713
70. Epinastine Hydrochloride [ep Monograph]
71. F17420
72. Epinastine Hydrochloride, >=98% (hplc), Solid
73. A857231
74. J-002209
75. Q27122286
76. Epinastine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
77. 1h-dibenz(c,f)imidazo(1,5-a)azepin-3-amine, 9,13b-dihydro-, Hydrochloride (1:1)
78. 3-amino-9,13b-dihydro-1h-dibenz(c,f)imidazo(1,5-a)azepine Hydrochloride, Dl-
79. Epinastine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
80. 2,4-diazatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine;hydron;chloride
81. Epinastine Hydrochloride For System Suitability, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 285.77 g/mol |
---|---|
Molecular Formula | C16H16ClN3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 0 |
Exact Mass | 285.1032752 g/mol |
Monoisotopic Mass | 285.1032752 g/mol |
Topological Polar Surface Area | 41.6 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 378 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Elestat |
PubMed Health | Epinastine (Into the eye) |
Drug Classes | Ophthalmologic Agent |
Drug Label | ELESTAT (epinastine HCl ophthalmic solution) 0.05% is a clear, colorless, sterile isotonic solution containing epinastine HCl, an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes. Epinast... |
Active Ingredient | Epinastine hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 0.05% |
Market Status | Prescription |
Company | Allergan |
2 of 4 | |
---|---|
Drug Name | Epinastine hydrochloride |
Drug Label | Epinastine HCl ophthalmic solution, 0.05% is a clear, colorless, sterile isotonic solution containing epinastine HCl, an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes.Epinastine HCl is r... |
Active Ingredient | Epinastine hydrochloride |
Dosage Form | Solution/drops; Solution |
Route | ophthalmic; Ophthalmic |
Strength | 0.05% |
Market Status | Tentative Approval; Prescription |
Company | Tesa Pharms; Breckenridge Pharm; Apotex; Sun Pharm Inds; Sandoz |
3 of 4 | |
---|---|
Drug Name | Elestat |
PubMed Health | Epinastine (Into the eye) |
Drug Classes | Ophthalmologic Agent |
Drug Label | ELESTAT (epinastine HCl ophthalmic solution) 0.05% is a clear, colorless, sterile isotonic solution containing epinastine HCl, an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes. Epinast... |
Active Ingredient | Epinastine hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 0.05% |
Market Status | Prescription |
Company | Allergan |
4 of 4 | |
---|---|
Drug Name | Epinastine hydrochloride |
Drug Label | Epinastine HCl ophthalmic solution, 0.05% is a clear, colorless, sterile isotonic solution containing epinastine HCl, an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes.Epinastine HCl is r... |
Active Ingredient | Epinastine hydrochloride |
Dosage Form | Solution/drops; Solution |
Route | ophthalmic; Ophthalmic |
Strength | 0.05% |
Market Status | Tentative Approval; Prescription |
Company | Tesa Pharms; Breckenridge Pharm; Apotex; Sun Pharm Inds; Sandoz |
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
34
PharmaCompass offers a list of Epinastine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Epinastine Hydrochloride manufacturer or Epinastine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Epinastine Hydrochloride manufacturer or Epinastine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Epinastine Hydrochloride API Price utilized in the formulation of products. Epinastine Hydrochloride API Price is not always fixed or binding as the Epinastine Hydrochloride Price is obtained through a variety of data sources. The Epinastine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Epinastine HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Epinastine HCl, including repackagers and relabelers. The FDA regulates Epinastine HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Epinastine HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Epinastine HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Epinastine HCl supplier is an individual or a company that provides Epinastine HCl active pharmaceutical ingredient (API) or Epinastine HCl finished formulations upon request. The Epinastine HCl suppliers may include Epinastine HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Epinastine HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Epinastine HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Epinastine HCl active pharmaceutical ingredient (API) in detail. Different forms of Epinastine HCl DMFs exist exist since differing nations have different regulations, such as Epinastine HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Epinastine HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Epinastine HCl USDMF includes data on Epinastine HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Epinastine HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Epinastine HCl suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Epinastine HCl Drug Master File in Japan (Epinastine HCl JDMF) empowers Epinastine HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Epinastine HCl JDMF during the approval evaluation for pharmaceutical products. At the time of Epinastine HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Epinastine HCl suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Epinastine HCl Drug Master File in Korea (Epinastine HCl KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Epinastine HCl. The MFDS reviews the Epinastine HCl KDMF as part of the drug registration process and uses the information provided in the Epinastine HCl KDMF to evaluate the safety and efficacy of the drug.
After submitting a Epinastine HCl KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Epinastine HCl API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Epinastine HCl suppliers with KDMF on PharmaCompass.
A Epinastine HCl CEP of the European Pharmacopoeia monograph is often referred to as a Epinastine HCl Certificate of Suitability (COS). The purpose of a Epinastine HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Epinastine HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Epinastine HCl to their clients by showing that a Epinastine HCl CEP has been issued for it. The manufacturer submits a Epinastine HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Epinastine HCl CEP holder for the record. Additionally, the data presented in the Epinastine HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Epinastine HCl DMF.
A Epinastine HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Epinastine HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Epinastine HCl suppliers with CEP (COS) on PharmaCompass.
A Epinastine HCl written confirmation (Epinastine HCl WC) is an official document issued by a regulatory agency to a Epinastine HCl manufacturer, verifying that the manufacturing facility of a Epinastine HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Epinastine HCl APIs or Epinastine HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Epinastine HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Epinastine HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Epinastine HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Epinastine HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Epinastine HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Epinastine HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Epinastine HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Epinastine HCl suppliers with NDC on PharmaCompass.
Epinastine HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Epinastine HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Epinastine HCl GMP manufacturer or Epinastine HCl GMP API supplier for your needs.
A Epinastine HCl CoA (Certificate of Analysis) is a formal document that attests to Epinastine HCl's compliance with Epinastine HCl specifications and serves as a tool for batch-level quality control.
Epinastine HCl CoA mostly includes findings from lab analyses of a specific batch. For each Epinastine HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Epinastine HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Epinastine HCl EP), Epinastine HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Epinastine HCl USP).